BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.Hematol Oncol Clin North Am. 2015;29:509-524. [PMID: 26043389 DOI: 10.1016/j.hoc.2015.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Shahidi M. Thrombosis and von Willebrand Factor. In: Islam MS, editor. Thrombosis and Embolism: from Research to Clinical Practice. Cham: Springer International Publishing; 2017. pp. 285-306. [DOI: 10.1007/5584_2016_122] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
2 Flood VH. Platelet-derived VWF in the stroke spotlight. Blood 2015;126:1640-1. [PMID: 26429965 DOI: 10.1182/blood-2015-08-661439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Michael M, Turner N, Elenberg E, Shaffer LG, Teruya J, Arar M, Hui SK, Smith RJ, Moake J. Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13. Clin Kidney J 2018;11:791-6. [PMID: 30524124 DOI: 10.1093/ckj/sfy010] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2018;2018:539-47. [PMID: 30504355 DOI: 10.1182/asheducation-2018.1.539] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
5 Arslan M, Yilmaz G, Mentese A, Yilmaz H, Karahan SC, Koksal I. Importance of endothelial dysfunction biomarkers in patients with Crimean-Congo hemorrhagic fever. J Med Virol 2017;89:2084-91. [PMID: 28628220 DOI: 10.1002/jmv.24881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
7 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chang JC. Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation. Blood Coagul Fibrinolysis 2018;29:585-95. [PMID: 30234545 DOI: 10.1097/MBC.0000000000000769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Francian A, Mann K, Kullberg M. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs. Int J Nanomedicine 2017;12:5149-61. [PMID: 28790822 DOI: 10.2147/IJN.S138787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
10 Subramaniam S, Jurk K, Hobohm L, Jäckel S, Saffarzadeh M, Schwierczek K, Wenzel P, Langer F, Reinhardt C, Ruf W. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 2017;129:2291-302. [PMID: 28223279 DOI: 10.1182/blood-2016-11-749879] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 20.8] [Reference Citation Analysis]
11 Lu Q, Hou Q, Cao K, Sun X, Liang Y, Gu M, Xue X, Zhao AZ, Dai C. Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease. JCI Insight 2021;6:e147716. [PMID: 34622800 DOI: 10.1172/jci.insight.147716] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Șalaru DL, Adam CA, Marcu DTM, Șimon IV, Macovei L, Ambrosie L, Chirita E, Sascau RA, Statescu C. Acute myocardial infarction and extensive systemic thrombosis in thrombotic thrombocytopenic purpura: A case report and review of literature. World J Clin Cases 2021; 9(27): 8104-8113 [PMID: 34621868 DOI: 10.12998/wjcc.v9.i27.8104] [Reference Citation Analysis]
13 Wu H, Jay L, Lin S, Han C, Yang S, Cataland SR, Masias C. Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura. Br J Haematol 2020;189:e18-20. [PMID: 32065383 DOI: 10.1111/bjh.16415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med 2021;10:536. [PMID: 33540569 DOI: 10.3390/jcm10030536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Tan Y, Zhao MH. Complement in glomerular diseases. Nephrology (Carlton) 2018;23 Suppl 4:11-5. [PMID: 30298653 DOI: 10.1111/nep.13461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
16 Sukumar S, Gavriilaki E, Chaturvedi S. Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. Thrombosis Update 2021;5:100062. [DOI: 10.1016/j.tru.2021.100062] [Reference Citation Analysis]